THE MERCK MANUAL: The Merck Manual of Diagnosis and Therapy
Print Topic

Sections

Chapters

Contact Dermatitis

-
-

Contact dermatitis (CD) is acute inflammation of the skin caused by irritants or allergens. The primary symptom is pruritus. Skin changes range from erythema to blistering and ulceration, often on or near the hands but occurring on any exposed skin surface. Diagnosis is by exposure history, examination, and sometimes skin patch testing. Treatment entails antipruritics, topical corticosteroids, and avoidance of causes.

CD is caused by irritants or allergens.

Irritant contact dermatitis (ICD)

ICD accounts for 80% of all cases of CD. It is a nonspecific inflammatory reaction to substances contacting the skin; the immune system is not activated. Numerous substances are involved, including

  • Chemicals (eg, acids, alkalis, solvents, metal salts)
  • Soaps (eg, abrasives, detergents)
  • Plants (eg, poinsettias, peppers)
  • Body fluids (eg, urine, saliva)

Properties of the irritant (eg, extreme pH, solubility in the lipid film on skin), environment (eg, low humidity, high temperature, high friction), and patient (eg, very young or old) influence the likelihood of developing ICD. ICD is more common among patients with atopic disorders, in whom ICD also may initiate immunologic sensitization and hence allergic CD.

Phototoxic dermatitis (see Reactions to Sunlight: Chemical photosensitivity) is a variant in which topical (eg, perfumes, coal tar) or ingested (eg, psoralens) agents generate damaging free radicals and inflammatory mediators only after absorption of ultraviolet light.

Allergic contact dermatitis (ACD)

ACD is a type IV cell-mediated hypersensitivity reaction that has 2 phases:

  • Sensitization to an antigen
  • Allergic response after reexposure

In the sensitization phase, allergens are captured by Langerhans cells (dendritic epidermal cells), which migrate to regional lymph nodes where they process and present the antigen to T cells. The process may be brief (6 to 10 days for strong sensitizers such as poison ivy) or prolonged (years for weak sensitizers such as sunscreens, fragrances, and glucocorticoids). Sensitized T cells then migrate back to the epidermis and activate on any reexposure to the allergen, releasing cytokines, recruiting inflammatory cells, and leading to the characteristic symptoms and signs of ACD.

In autoeczematization, epidermal T cells activated by an allergen migrate locally or through the circulation to cause dermatitis at sites remote from the initial trigger. However, contact with fluid from vesicles or blisters cannot trigger a reaction elsewhere on the patient or on another person.

Multiple allergens cause ACD (see Table 2: Dermatitis: Causes of Allergic Contact DermatitisTables), and cross-sensitization among agents is common (eg, between benzocaine and paraphenylenediamine). Cross-sensitization means that exposure to one substance can result in an allergic response after exposure to a different but related substance. Toxicodendron sp plants (eg, poison ivy, poison oak, poison sumac) account for a large percentage of ACD, including moderate and severe cases. The offending allergen is urushiol.

Table 2

PrintOpen table in new window Open table in new window

ACD variants include photoallergic CD and systemically induced ACD. In photoallergic CD (see Reactions to Sunlight: Chemical photosensitivity), a substance becomes sensitizing only after it undergoes structural change triggered by ultraviolet light. Typical causes include aftershave lotions, sunscreens, and topical sulfonamides. Reactions may extend to non–sun-exposed skin. In systemically induced ACD, ingestion of an allergen after topical sensitization causes diffuse dermatitis (eg, oral diphenhydramine after sensitization with topical diphenhydramine).

ICD

ICD is more painful than pruritic. Signs range from mild erythema to hemorrhage, crusting, erosion, pustules, bullae, and edema.

ACD

In ACD, the primary symptom is intense pruritus; pain is usually the result of excoriation or infection. Skin changes range from transient erythema through vesiculation to severe swelling with bullae, ulceration, or both. Changes often occur in a pattern, distribution, or combination that suggests a specific exposure, such as linear streaking on an arm or leg (eg, due to brushing against poison ivy) or circumferential erythema (under a wristwatch or waistband). Linear streaks are almost always indicative of an external allergen or irritant. Any surface may be involved, but hands are the most common surface due to handling and touching potential allergens. With airborne exposure (eg, perfume aerosols), areas not covered by clothing are predominantly affected. The dermatitis is typically limited to the site of contact but may later spread due to scratching and autoeczematization. In systemically induced ACD, skin changes may be distributed over the entire body. The eruption usually begins within 24 to 48 h after exposure to the allergen.

  • Clinical evaluation
  • Sometimes patch testing

CD can often be diagnosed by skin changes and exposure history. The patient's occupation, hobbies, household duties, vacations, clothing, topical drug use, cosmetics, and spouse's activities must be considered. The “use” test, in which a suspected agent is applied far from the original area of dermatitis, usually on the flexor forearm, is useful when perfumes, shampoos, or other home agents are suspected.

Patch testing is indicated when ACD is suspected and does not respond to treatment. In patch testing, standard contact allergens are applied to the upper back using adhesive-mounted patches containing minute amounts of allergen or plastic (Finn) chambers containing allergen held in place with porous tape. Thin-layer rapid use epicutaneous (TRUE) patch testing involves 2 adhesive strips that can be applied and interpreted by any health care practitioner. Skin under the patches is evaluated 48 and 96 h after application. False-positive results occur when concentrations provoke an irritant rather than an allergic reaction, when reaction to one antigen triggers a nonspecific reaction to others, or with cross-reacting antigens. False-negative results occur when patch allergens do not include the offending antigen. Definitive diagnosis requires a history of exposure to the test agent in the original area of dermatitis.

Table 3

PrintOpen table in new window Open table in new window

Resolution may take up to 3 wk. Reactivity is usually lifelong. Patients with photoallergic CD can have flares for years when exposed to sun (persistent light reaction).

  • Avoidance of offending agents
  • Supportive care (eg, cool compresses, dressings, antihistamines)
  • Corticosteroids (most often topical but sometimes oral)

CD is prevented by avoiding the trigger; patients with photosensitive CD should avoid exposure to sun.

Topical treatment includes cool compresses (saline or Burow solution) and corticosteroids; patients with mild to moderate ACD are given mid-potency topical corticosteroids (eg, triamcinolone 0.1% ointment or betamethasone valerate cream 0.1%). Oral corticosteroids (eg, prednisone 60 mg once/day for 7 to 14 days) can be used for severe blistering or extensive disease. Systemic antihistamines (eg, hydroxyzine, diphenhydramine) help relieve pruritus; antihistamines with low anticholinergic potency, such as low-sedating H1 blockers, are not as effective. Wet-to-dry dressings can soothe oozing blisters, dry the skin, and promote healing.

  • Contact dermatitis (CD) can be caused by irritants (eg, plants, soaps, chemicals, body fluids, comprising 80% of cases) or allergens (comprising 20% of cases).
  • Symptoms can include predominantly pain (for irritant contact dermatitis) or pruritus (for allergic contact dermatitis).
  • Diagnosis is usually clinical.
  • Do patch testing when ACD is suspected and treatment has been ineffective.
  • Treatments commonly include cool compresses, topical corticosteroids, and systemic antihistamines as needed for pruritus.

Last full review/revision October 2012 by Karen McKoy, MD, MPH

Copyright     © 2010-2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.    Privacy    Terms of Use